Skip to content

Guardant Health GH Inventories

Inventories at other companies

Myriad Genetics logo
Myriad GeneticsMYGN
$27.9M-1.4%
NeoGenomics logo
NeoGenomicsNEO
$27.14M-20.6%
Illumina logo
IlluminaILMN
$629M-9.2%
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
$11.21M+29.0%
Natera, Inc. logo
Natera, Inc.NTRA
$70.72M+40.4%
Insight Molecular Diagnostics Inc. logo
Insight Molecular Diagnostics Inc.IMDX
$382K-16.8%

Other financials

Income statement

See full
Revenue$301.7M+48.3%
Gross profit$196.7M+52.8%
Operating income-$121.4M-9.3%
Net income-$112.1M-17.8%
EPS (diluted)-$0.85-10.4%

Balance sheet

See full
Cash & equivalents$1.1B+37.0%
Total debt$1.7B+30.5%
Total equity-$181.1M+27.8%
Total assets$1.9B+42.5%

Cash flow

See full
Operating cash flow-$65.6M-4.7%
CapEx$5.6M+25.1%
Free cash flow-$71.2M-6.0%

Valuation

See full
Market cap$19.04B+255%
Enterprise value$19.65B+229%
P/S17.6×+11.2×

Profitability

See full
Gross margin64.9%+3.6pp
Operating margin-41.4%-9.4pp
Net margin-40.1%-8.1pp
FCF margin-22%-6.7pp

Returns & leverage

See full
Return on equity-438.1%-1,655pp
Debt / equity
Current ratio4.7×+0.6×

Where this comes from

Reported directly by Guardant Health in its filing.

Tagged under the XBRL concept us-gaap:InventoryNet.

The official record: Guardant Health’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Guardant Health's inventories.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Guardant Health's inventories?
Guardant Health (GH) reported inventories of $83.85M in Q1 2026.
How has Guardant Health's inventories changed year-over-year?
Guardant Health's inventories increased by 8.5% year-over-year, from $77.26M to $83.85M.
What is the long-term trend for Guardant Health's inventories?
Over 5 years (2020 to 2025), Guardant Health's inventories has grown at a 30.5% compound annual growth rate (CAGR), from $22.72M to $85.88M.
What does inventories mean?
Total inventory including raw materials, work-in-progress, and finished goods, valued at the lower of cost or net realizable value.